MDS Current Trials UK
We aim to list an easily understandable description of any MDS clinical trials currently opened to recruitment in the UK.
Patients will be able to read up on the details of these trials and use this information to discuss with their consultants or nurses.
Not all patients can be enrolled in drug trials - as not every patient will fit the necessary inclusion criteria, which need to be followed very strictly. However, if a particular clinical trial drug is considered an option by the haematologist, it is sometimes possible to obtain the drug outside the trial, on the basis of compassionate use.
All the trials listed in this page have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust
Paper of the Month
Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure
IPSS-R MDS Risk Assessment Calculator
Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndromes Risk Assessment Calculator
MDS Fact Sheet
Varicella Vaccine in MDS
Urgent Clarification on varicella vaccine policy
Current advice from the UK MDS Forum is not to give the Live Varicella Vaccine to patients with MDS.
Please read below correspondence between Professor Salisbury and Dr George Follows, the latter on behalf of the CLL Forum, on the varicella vaccine policy.
This is an external link to the British Society for Haematology Click here
NICE Guideline
Lenalidomide for treating myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality.
BSH Guidelines
Links
External links to another websites